Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.

Lancet (London, England) - 3 Sept 2016

Hiley Crispin T, Le Quesne John, Santis George, Sharpe Rowena, de Castro David Gonzalez, Middleton Gary, Swanton Charles

Abstract excerpt

Lung cancer diagnostics have progressed greatly in the previous decade. Development of molecular testing to identify an increasing number of potentially clinically actionable genetic variants, using smaller samples obtained via minimally invasive techniques, is a huge challenge. Tumour heterogeneity and cancer evolution in response to therapy means that repeat biopsies or circulating biomarkers are likely to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Receptor Protein-Tyrosine Kinases

Share to Severity of Illness Index

Source

Identifiers

PMID: 27598680
DOI: 10.1016/S0140-6736(16)31340-X

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.PMID 27598680Read ↗

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Semantic proximity Read ↗

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

Molecular Diagnostics in Non-Small Cell Lung Carcinoma.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

Recent advance of next-generation sequencing in patients with lung cancer.Semantic proximity Read ↗

Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practiceSemantic proximity Read ↗

Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression.Semantic proximity Read ↗

Lung Cancer GenomicsSemantic proximity Read ↗

Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsSemantic proximity Read ↗

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.